Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.
Stocks · News reference
BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.
8-K filing — BlossomHill Therapeutics, Inc. (BLSM)
Filed: 2026-09-18 AccNo: 0001193125-26-395031 Size: 239 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits